CT
DNA icon

Clearstead Trust’s Ginkgo Bioworks DNA Stock Holding History

Clearstead Trust’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-58
Closed -$2.7K – 435
2024
Q1 		$2.7K Hold
58
– – ﹤0.01% 396
2023
Q4 		$3.93K Hold
58
– – ﹤0.01% 372
2023
Q3 		$4.21K Buy
+58
New +$4.64K ﹤0.01% 390

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Clearstead Trust's DNA Position: Q2 2024 in Review

Clearstead Trust sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 58 shares — an estimated $2.7K sold.

Clearstead Trust first reported a position in DNA in Q3 2023 and held it in 3 quarters. The position peaked at $4.21K in Q3 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Clearstead Trust reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Clearstead Trust sold 58 Ginkgo Bioworks shares in Q2 2024, an estimated $2.7K.
  • Clearstead Trust first reported a position in Ginkgo Bioworks in Q3 2023 and held it in 3 quarters.
  • Clearstead Trust's Ginkgo Bioworks position peaked at $4.21K in Q3 2023.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Clearstead Trust's 13F filing for Q2 2024, filed 9 Aug 2024.